Research Site

Murcia 30720

3 studies enrolling now · 17 studies all time

What they study most

Asthma, B-Cell Non Hodgkin Lymphoma, Breast Cancer, Breast Cancer, Early Breast Cancer, COPD, Cardiovascular Disease, Chronic Lymphocytic Leukemia, Chronic Obstructive Pulmonary Disease, ER-Positive HER2-Negative Breast Cancer, Generalized Myasthenia Gravis, Heart Failure With Reduced Ejection Fraction, Hyperkalaemia

Studies at this site

• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer — Recruiting now
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) — Running, not enrolling
• A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone — Completed
• Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis — Stopped early
• An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer — Stopped early
• Observational Study of Obstructive Lung Disease (NOVELTY) — Completed
• Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis — Completed
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL — Completed
• Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients — Stopped early
• Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) — Stopped early